What does Autonomix Medical do?
Autonomix Medical, Inc. is a Nasdaq-listed, development-stage medical device company with no commercial product sales. It is building a catheter platform intended to sense weak peripheral nerve signals, ablate selected nerves with radiofrequency energy, and verify the resulting change—a “sense, treat, verify” model. Its lead indication is severe pancreatic-cancer pain, with longer-term possibilities in hypertension, chronic pain, cardiology, pulmonology, gastroenterology, and urology.
What is the company actually developing?
The platform combines disposable sensing and RF ablation catheters, an energy generator, and software. Peripheral nerve signals may be only 1 to 2 microvolts, far weaker than conventional electrophysiology signals. Autonomix places amplification and digitization near the electrodes to preserve them before degradation. Its official investor overview explains the precision-denervation approach.
| Identity item | Autonomix Medical profile | Why it matters |
|---|---|---|
| Development stage | Pre-revenue medical-device company | Value depends on clinical, regulatory, financing, and commercialization milestones rather than current earnings. |
| Lead indication | Pancreatic cancer-related pain | A focused first indication can produce procedural learning before broader platform expansion. |
| Core approach | Transvascular neural sensing plus RF ablation | Uses familiar catheter-lab access while trying to add objective nerve localization and treatment verification. |
| Regulatory concept | FDA De Novo pathway | The lack of a directly comparable predicate device increases both differentiation potential and regulatory uncertainty. |
How could Autonomix Medical make money?
Autonomix currently generates no product revenue. Its proposed model is procedure-based: recurring single-use catheter sales would scale with procedures in hospital catheter laboratories. The generator and software would support the workflow, while sensing and ablation catheters would provide the recurring stream. Licensing, partnerships, and standalone sensing are additional possibilities.
Which revenue streams are most plausible?
| Potential stream | Economic logic | Current status |
|---|---|---|
| Disposable sensing catheter | Recurring revenue per procedure; potentially useful with or without ablation. | Prototype and development stage; not cleared for U.S. marketing. |
| Disposable RF ablation catheter | Recurring procedure-linked sales for nerve treatment. | Clinical validation and product development remain underway. |
| Generator and software | Supports workflow, visualization, and system control with relatively lower recurring frequency. | Commercial configuration has not been finalized. |
| Partnership or licensing | Could exchange platform or field rights for upfront, milestone, royalty, or co-development economics. | A strategic option, not a disclosed contracted revenue stream. |
The fiscal 2026 Form 10-K confirms this prospective status. Key partners are clinical sites, manufacturers, regulators, and potential medtech collaborators; key resources are patents, clinical data, engineering, and capital.
Why does the “sense, treat, verify” platform matter?
Autonomix is not merely trying to ablate tissue; RF energy and catheter interventions are established. Its challenge is identifying relevant nerve fibers, reaching them minimally invasively, and confirming a functional change. Where denervation often relies on anatomy and indirect assumptions, Autonomix seeks to add real-time neural-signal guidance.
What could become a durable competitive resource?
The strongest resource argument combines sensing architecture, procedural know-how, patents, and clinical data. The FY2026 filing disclosed 18 patent families, 75 issued patents, and 37 pending applications, generally expiring from 2033 to 2039. A May 2026 patent added claims for transvascular monitoring, treatment through a lumen wall, multi-site sensing, and real-time validation. The official patent announcement describes that closed-loop concept.
Why is the platform thesis still unproven?
Patent breadth does not guarantee clinical utility, regulatory clearance, reimbursement, manufacturability, or adoption. The proprietary sensing catheter was not used in the initial PoC 1 human trial; that study relied on commercially available RF equipment. Therefore, the most important claim—integrated sensing improving targeting and consistency—still requires direct human validation. In VRIO terms, the IP may be valuable and relatively rare, but the “organized to capture value” and “difficult to imitate in clinical practice” tests remain open.
What do the clinical results and strategic history show?
Autonomix’s history reflects tension between platform breadth and indication focus. Management envisions multiple nervous-system applications, but the company first needs credible evidence in one narrow use case before broader reuse can be valued.
-
2012-2021The earliest disclosed patent filings established foundational nerve-modulation and micro-ablation concepts. In 2021, cardiology field rights were licensed to Impulse Medical, separating one major application from the parent platform.
-
July 2023Autonomix agreed to terminate that cardiology license, setting up the later reacquisition of worldwide rights and restoring broader strategic optionality.
-
January 2024The company completed its Nasdaq IPO and regained exclusive worldwide cardiology rights through a warrant-based transaction valued at $8.0 million at the offering price.
-
2024-April 2025PoC 1 enrolled 20 patients with severe pancreatic cancer pain; 19 were treated. The trial produced rapid pain-reduction signals and a crucial procedural difference between femoral and brachial access.
-
Fiscal 2026PoC 2 broadened the population, but early outcomes diverged from PoC 1. Enrollment was paused while management reassessed vascular access, anatomic targeting, patient selection, and procedure design.
-
April 9, 2026An ethics committee approved a revised protocol focused on severe pancreatic cancer pain, refined procedural technique, further RF catheter validation, and initial sensing-catheter use.
-
June-July 2026Autonomix highlighted a standalone neural-sensing program, completed a 1-for-21 reverse split, regained Nasdaq bid-price compliance, and raised additional gross proceeds through a warrant inducement.
What did PoC 1 demonstrate?
The April 2025 update reported 19 of 20 enrolled patients treated, with no device- or procedure-related serious adverse events. All 16 femoral-access patients responded, while three brachial-access patients did not—an important procedural lesson. Mean VAS pain reduction was 43.6% at seven days and 49.7% at four to six weeks. The official PoC 1 release reported 100% of responders opioid-free at seven days and 73% at four to six weeks.
What changed after the expansion study?
The broader PoC 2 cohort did not consistently reproduce PoC 1’s early pattern, so management paused enrollment and narrowed the strategy. That may improve study design but lengthens the path. A January 2026 subgroup analysis still found rapid pain relief among PoC 1 responders across Stage 2 through Stage 4 disease: 93.75% of 16 responders improved from severe to mild or moderate pain at seven days. The company’s ASCO GI update summarizes the data, but prospective reproducibility remains essential.
What does the latest financial package show?
The latest full financial package is the Form 10-K for the fiscal year ended March 31, 2026. It shows a company accelerating clinical and administrative spending without revenue. The income statement is therefore best read as a cash-consumption and financing-capacity statement rather than a margin story.
| Metric | FY2026 | FY2025 | Interpretation |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | The platform remains pre-commercial. |
| R&D expense | $7.1M | $4.7M | Up 51%, primarily from clinical-trial and product-development activity plus stock-based effects. |
| G&A expense | $9.9M | $6.9M | Up 44%, including stock-option cancellation expense and higher legal and professional fees. |
| Total operating expense | $17.0M | $11.6M | Up 47%; spending growth exceeded the company’s available cash growth. |
| Net loss | $16.7M | $11.4M | Loss widened by $5.3M as the program advanced and corporate costs increased. |
| Interest income | $0.3M | $0.4M | Cash yield provided only a small offset to operating costs. |
Why do accounting loss and cash burn differ?
FY2026 net loss was $16.7 million, while operating cash use was $12.3 million. The difference reflects non-cash items, including $3.7 million of stock-option cancellation expense, $0.5 million of stock-based compensation, and a $0.3 million equity-line commitment fee. For valuation, operating cash burn is the more immediate financing metric, while the income statement still reveals the underlying cost structure.
How strong are liquidity and capital access?
Liquidity is the most immediate financial constraint. At March 31, 2026, Autonomix had $7.0 million of cash, $7.6 million of total assets, $1.7 million of current liabilities, and $5.9 million of working capital. It had no conventional interest-bearing debt on the balance sheet, but the absence of debt does not equal financial strength when annual operating cash use is $12.3 million and the company remains dependent on equity and warrants.
| Liquidity item | Amount | Period | Research implication |
|---|---|---|---|
| Cash and cash equivalents | $7.0M | March 31, 2026 | Less than one year of FY2026 operating cash use at the recent run rate. |
| Working capital | $5.9M | March 31, 2026 | Positive, but insufficient for the full clinical and commercial plan. |
| Financing cash inflow | $10.2M | FY2026 | Equity and warrant transactions largely funded the operating deficit. |
| Estimated additional need | $25M-$32M | Management estimate in FY2026 10-K | Funding through initial commercial launch may require repeated transactions and dilution. |
| July warrant exercise | Approximately $2.6M gross | July 13, 2026 | Extends liquidity but adds common shares and two new warrant series. |
Why is dilution part of the operating model?
A 1-for-21 reverse split became effective June 24, 2026, reducing 11.4 million pre-split shares to roughly 542,000 post-split shares. The reverse-split Form 8-K retained 500 million authorized shares. On July 13, Series C warrants covering 428,731 post-split shares were repriced to $6.00, producing expected gross proceeds of about $2.6 million. Two new warrant series each cover another 428,731 shares at $5.75. The July 2026 Form 8-K shows why fully diluted shares matter more than the headline count.
Who competes with Autonomix, and what could become a moat?
Autonomix spans electrophysiology, pain intervention, neuromodulation, and renal denervation. Its FY2026 filing names Medtronic, Johnson & Johnson, Abbott, and Boston Scientific as relevant large medtech competitors. They have regulatory, manufacturing, hospital, evidence, and commercial capabilities that Autonomix lacks.
| Competitive force | Existing alternative or rival | Autonomix differentiation claim | What must be proven |
|---|---|---|---|
| Large-device competition | Medtronic, Johnson & Johnson, Abbott, Boston Scientific | Peripheral nerve sensing at very low amplitudes integrated with treatment verification. | Clinical superiority or workflow value sufficient to overcome rivals’ scale. |
| Pancreatic pain standard of care | Opioids, neurolytic injections, celiac plexus procedures | Transvascular access intended to improve targeting and reduce collateral damage. | Durable pain benefit, safety, and comparative value in controlled studies. |
| Procedural substitutes | Percutaneous and endoscopic ultrasound-guided approaches | Catheter-lab workflow with potential real-time functional feedback. | Training simplicity, procedure time, reimbursement, and adoption economics. |
| Imitation risk | Design-arounds or alternative sensing methods | 18 patent families and application-specific coverage across organs. | Enforceable claims that competitors cannot cheaply bypass. |
What does market position mean for a pre-commercial company?
AMIX has no commercial market share. Its current “position” is scientific and strategic: early human pain data, a broad patent estate, and a differentiated technical thesis. The company states that it is not aware of another organization developing the same transvascular sensing-and-ablation method for pancreatic cancer pain. That is useful evidence of whitespace, but not proof of dominance. A large medtech company could compete through adjacent platforms, acquisition, partnership, or a different clinical solution.
Who owns AMIX and how is it governed?
Autonomix has one class of common stock with conventional economic and voting rights rather than a founder-controlled dual-class structure. According to the company’s Form 10-K/A, directors and executive officers as a group beneficially owned 363,024 pre-split shares, or 3.2%, as of June 1, 2026. Percentages are economically unchanged by the later 1-for-21 split, although share counts were divided proportionately.
| Holder or group | Beneficial shares | Percent | Why it matters |
|---|---|---|---|
| All directors and executive officers, 9 persons | 363,024 | 3.2% | Insider alignment exists but does not create voting control. |
| Walter Klemp | 150,750 | 1.3% | Largest individually disclosed board/management stake in the table. |
| Landy Toth | 101,315 | Less than 1% | Co-founder and technology contributor, but without controlling ownership. |
| Brad Hauser, CEO | None disclosed | 0% | CEO incentives were primarily compensation-based rather than a disclosed equity stake at that date. |
What governance signals deserve attention?
The board has Audit, Compensation, and Nominating and Corporate Governance committees. The Audit Committee had three independent directors, and Jonathan Foster was identified as its financial expert. The fiscal 2026 Form 10-K/A also reported that none of the named executive officers held equity awards at March 31, 2026 after option cancellations. CEO Brad Hauser received total FY2026 compensation of $670,176, including $202,176 of non-equity incentive compensation; CFO Trent Smith received $381,763. For a small, financing-dependent issuer, investors should compare compensation, ownership, and milestone delivery closely.
Which opportunities, risks, and KPIs matter most?
The opportunity set is broad, but the next steps are narrow: reproduce results in severe pancreatic-cancer pain, introduce proprietary sensing in humans, secure capital, and advance toward a U.S. investigational-device study. Wider applications remain optionality until those milestones are met.
Which risks could most quickly change the story?
| Risk | Evidence | Financial or strategic impact |
|---|---|---|
| Clinical reproducibility | PoC 2 outcomes diverged from PoC 1 and enrollment was paused. | Could require redesign, delay U.S. trials, or weaken the platform thesis. |
| Going concern and financing | $67.1M accumulated deficit and $12.3M FY2026 operating cash use. | May force repeated equity transactions, program reductions, or unfavorable terms. |
| Regulatory uncertainty | Novel combination technology is expected to pursue De Novo classification. | Additional studies or a different pathway could increase time and cost. |
| Single-manufacturer dependence | No internal manufacturing facilities; prototype devices remain hand-built. | Supplier disruption, quality issues, or poor yields could delay trials and commercialization. |
| Reimbursement and adoption | No approved product, established procedure price, or reimbursement history. | Even a cleared device may face slow procurement and uncertain procedure economics. |
| Capital-market dilution | Reverse split followed by a large warrant exercise and two new warrant series. | Per-share value may lag enterprise progress if the denominator expands rapidly. |
How should the opportunity be framed?
A validated sensing-and-ablation platform could support multiple indications, recurring disposables, partnerships, and strategic interest. Conversely, AMIX has no revenue, limited cash, a going-concern warning, and no pivotal U.S. trial. Regaining Nasdaq minimum-bid compliance removed one immediate listing issue, as shown in the official compliance Form 8-K, but did not change the clinical or financing burden.
What is the key takeaway for valuation and research?
A conventional near-term revenue and EBITDA DCF is unsuitable because Autonomix has no commercial base. A more defensible model is probability-adjusted and milestone-driven, with scenarios for clinical success, regulatory and launch timing, procedure adoption, catheter pricing, gross margin, operating expense, and dilution.
Which assumptions drive intrinsic value?
- Probability of technical and clinical success: whether proprietary sensing improves targeting and whether refined trials reproduce durable pain outcomes.
- Time to clearance: management has discussed a possible 2028 timeframe, but delays materially reduce present value and increase financing needs.
- Procedure economics: catheter price, hospital reimbursement, procedure time, training burden, disposable gross margin, and repeat utilization.
- Capital requirements: the company estimated another $25 million to $32 million through initial commercial launch, before allowing for possible overruns.
- Dilution: fully diluted shares may change substantially through warrant exercises, new placements, equity lines, and future offerings.
- Platform expansion: renal sensing, hypertension, cardiology, and other pain indications should be modeled as separate, lower-probability options rather than embedded as certain revenue.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.